$TWST

Green Paula sold $62K of TWST

Green Paula (SVP of Human Resources) sold 884 shares of Twist Bioscience Corp (TWST) at $69.84 on 2026-06-08.

Original reporting
SEC EDGAR · Green Paula
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

The disclosure updates the insider ownership record and may marginally influence sentiment, but it does not introduce new operational, financial, or regulatory information.

02

Market read

Company-specific insider selling disclosure; generally low trading impact absent additional fundamental catalysts.

03

What to watch

Insider sales often reflect diversification, taxes, or pre-planned liquidity needs; the article provides no rationale or follow-on buying.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10 for a sale executed 2026-06-08

Background

The article is a primary SEC Form 4 insider transaction disclosure for Twist Bioscience.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience disclosed an insider open-market sale: SVP of Human Resources Green Paula sold 884 shares at $69.8442 on 2026-06-08 via Form 4.

Expected impact

Likely limited/short-lived impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is primary-source and company-specific, but the transaction is modest in size and is an open-market sale by an HR SVP, not a buy or a large block tied to a corporate event.

Market effects

No clear read-across to biotech tools/biomanufacturing beyond routine insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is not explicitly tied to a 10b5-1 plan, some traders may interpret it as a stronger near-term caution signal than typical scheduled selling.

Key entities

  • Twist Bioscience Corp

    Company whose insider transaction was reported on SEC Form 4.

  • Green Paula

    SVP of Human Resources who sold 884 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.